PDGFRB - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	Regulation of actin dynamics for phagocytic cup formation Role of ABL in ROBO-SLIT signaling Role of ABL in ROBO-SLIT signaling Myogenesis Myogenesis RHO GTPases Activate WASPs and WAVEs HDR through Single Strand Annealing (SSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Cyclin D associated events in G1 RUNX1 regulates transcription of genes involved in differentiation of HSCs RUNX2 regulates osteoblast differentiation FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	ATP Imatinib Dasatinib N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide Nilotinib XL228 Bosutinib 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA Myristic acid PD-166326 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide Regorafenib Ponatinib Fostamatinib Brigatinib Radotinib Asciminib Umbralisib	Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Chronic myeloid leukemia (CML)
Novel	ABL2	ABL proto-oncogene 2, non-receptor tyrosine kinase	Role of ABL in ROBO-SLIT signaling Role of ABL in ROBO-SLIT signaling RAC1 GTPase cycle RAC3 GTPase cycle Negative regulation of FLT3	ATP Dasatinib XL228 K-00546 Fostamatinib
Novel	ARAF	A-Raf proto-oncogene, serine/threonine kinase	RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	ATP	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel	BAG1	BAG cochaperone 1	Regulation of HSF1-mediated heat shock response	(2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
Novel	CAV1	caveolin 1	Triglyceride catabolism eNOS activation NOSTRIN mediated eNOS trafficking Thyroxine biosynthesis Basigin interactions Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability RHOA GTPase cycle Extra-nuclear estrogen signaling RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RAC3 GTPase cycle RHOF GTPase cycle FOXO-mediated transcription of cell cycle genes RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways		Congenital generalized lipodystrophy (CGL)
Novel	CAV3	caveolin 3	Smooth Muscle Contraction Smooth Muscle Contraction		Limb-girdle muscular dystrophy (LGMD) Caveolinopathies, including: Limb-girdle muscular dystrophy (LGMD) 1C; Rippling muscle disease (RMD); Idiopathic hyperCKemia; Distal myopathy with decreased caveolin 3; Hypertrophic cardiomyopathy (HCM) Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
Novel	CBL	Cbl proto-oncogene	Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel	CDK14	cyclin dependent kinase 14
Novel	CDX1	caudal type homeobox 1
Novel	CEP76	centrosomal protein 76	Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane AURKA Activation by TPX2
Novel	CHRM3	cholinergic receptor muscarinic 3	Muscarinic acetylcholine receptors Acetylcholine regulates insulin secretion G alpha (q) signalling events	Cevimeline Tramadol Succinylcholine Trospium Ziprasidone Disopyramide Amitriptyline Ipratropium Olanzapine Metixene Terfenadine Clozapine Doxylamine Trihexyphenidyl Oxyphencyclimine Procyclidine Loxapine Carbamoylcholine Hyoscyamine Cyproheptadine Meperidine Imipramine Methscopolamine bromide Chlorpromazine Darifenacin Haloperidol Tridihexethyl Anisotropine methylbromide Nortriptyline Amoxapine Cinnarizine Atropine Thiopental Nicardipine Paroxetine Homatropine methylbromide Trimipramine Scopolamine Benzquinamide Propiomazine Dicyclomine Tropicamide Brompheniramine Maprotiline Methantheline Glycopyrronium Bethanechol Tolterodine Oxybutynin Promethazine Pilocarpine Doxepin Desipramine Ketamine Quetiapine Mivacurium Diphenidol Aripiprazole Chlorprothixene Pancuronium Pipecuronium Methotrimeprazine Tiotropium Solifenacin Isopropamide Acetylcholine Arecoline Mepenzolate ALKS 27 Pizotifen Fesoterodine Methacholine Hexocyclium Aclidinium Umeclidinium Trimebutine Dosulepin Viloxazine Etoperidone Imidafenacin Butylscopolamine Homatropine Thonzylamine Revefenacin Propiverine Rociverine Diphemanil Aripiprazole lauroxil
Novel	COPA	coat protein complex I subunit alpha	COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic
Novel	COPB1	coat protein complex I subunit beta 1	Neutrophil degranulation COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic
Novel	CRK	CRK proto-oncogene, adaptor protein	ARMS-mediated activation ARMS-mediated activation Downstream signal transduction Regulation of actin dynamics for phagocytic cup formation p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAP1 and RAC1 MET receptor recycling Regulation of signaling by CBL FCGR3A-mediated phagocytosis
Novel	EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Respiratory syncytial virus (RSV) attachment and entry Developmental Lineage of Mammary Gland Myoepithelial Cells	Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Poziotinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib Mobocertinib Almonertinib Amivantamab	Laryngeal cancer Cervical cancer Oral cancer Gastric cancer Choriocarcinoma Esophageal cancer Glioma Bladder cancer
Novel	EIF2AK2	eukaryotic translation initiation factor 2 alpha kinase 2	ISG15 antiviral mechanism Inhibition of PKR SUMOylation of immune response proteins Interferon alpha/beta signaling Evasion by RSV of host interferon responses PKR-mediated signaling	Indomethacin H-89 Fostamatinib
Novel	ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Breast cancer Cervical cancer Cholangiocarcinoma Pancreatic cancer Gastric cancer Ovarian cancer Choriocarcinoma Endometrial Cancer Bladder cancer
Novel	FAXDC2	fatty acid hydroxylase domain containing 2
Novel	FGFR1	fibroblast growth factor receptor 1	Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
Novel	FYN	FYN proto-oncogene, Src family tyrosine kinase	GPVI-mediated activation cascade Signaling by ERBB2 PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Nef and signal transduction Cell surface interactions at the vascular wall FCGR activation PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling DAP12 signaling EPH-Ephrin signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Nephrin family interactions NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth Co-stimulation by CD28 CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway Co-inhibition by CTLA4 EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse Ephrin signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling CRMPs in Sema3A signaling VEGFA-VEGFR2 Pathway Dectin-2 family CD209 (DC-SIGN) signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Platelet Adhesion to exposed collagen Reelin signalling pathway Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF1 (M-CSF) in myeloid cells FLT3 signaling through SRC family kinases Antigen activates B Cell Receptor (BCR) leading to generation of second messengers High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Dasatinib Triglyme Fostamatinib Zotiraciclib

Search Results for: PDGFRB